Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: An observational study

被引:49
作者
Haider, Ahmad
Saad, Farid [1 ,2 ]
Doros, Gheorghe [3 ]
Gooren, Louis [4 ,5 ]
机构
[1] Bayer Pharma, Global Med Affairs Androl, D-13353 Berlin, Germany
[2] Gulf Med Univ, Sch Med, Ajman, U Arab Emirates
[3] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA
[4] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
[5] Androconsult, Chiang Mai, Thailand
关键词
Obesity; Diabetes mellitus type 2; Testosterone; Waist circumference; Weight loss; LATE-ONSET HYPOGONADISM; ALL-CAUSE MORTALITY; MIDDLE-AGED MEN; METABOLIC SYNDROME; WAIST CIRCUMFERENCE; INSULIN-RESISTANCE; PROSTATE-CANCER; OLDER MEN; DEFICIENCY; THERAPY;
D O I
10.1016/j.orcp.2013.10.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Treatment of obesity with diet and exercise may have short-term success but longer-term maintenance of weight loss is less successful. Obesity is associated with a reduction of serum testosterone, and, vice versa, a reduction in serum testosterone is associated with obesity and features of the metabolic syndrome. Objective: To investigate whether restoring serum testosterone to normal in hypogonadal obese men is beneficial with regard to weight loss and improvement of the metabolic syndrome. Methods: A prospective registry accumulated to 181 men over five years (mean serum testosterone 10.06 +/- 1.3 nmol/L (N > 12.1), body mass index (BMI) >= 30 kg/m(2). Of these men, 72 had diabetes mellitus type 2. All received parenteral testosterone undecanoate 1000 mg/12 weeks for up to five years. Results: Waist circumference (cm) decreased from 111.2 +/- 7.54 to 100.46 +/- 7.1, weight (kg) from 114.71 +/- 11.59 to 93.2 +/- 8.49, BMI (kg/m(2)) from 36.72 +/- 3.72 to 30.2 +/- 2.59 (all variables statistically significant vs. baseline (p < 0.0001) and each year compared to the previous year (p < 0.0001)). In the 72 diabetic men, waist circumference (cm) decreased from 112.93 +/- 7.16 to 101.48 +/- 7.24, weight (kg) from 116.94 +/- 11.62 to 94.42 +/- 9.42, BMI (kg/m(2)) from 37.71 +/- 3.5 to 30.95 +/- 2.69 (all variables statistically significant vs. baseline (p < 0.0001) and each year compared to the previous year (p < 0.0001)). In all men serum glucose, HbA(1c), lipid profiles and blood pressure improved significantly. Testosterone treatment as assessed by hemoglobin, hematocrit, serum prostate specific antigen (PSA) and occurrence of prostate cancer was acceptably safe. Conclusions: Normalizing serum testosterone in obese hypogonadal men, also in those with diabetes type 2, improved their metabolic state. (C) 2013 Asian Oceanian Association for the Study of Obesity. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:E339 / E349
页数:11
相关论文
共 51 条
[21]   Prediction of Metabolic Syndrome by Low Serum Testosterone Levels in Men Results From the Study of Health in Pomerania [J].
Haring, Robin ;
Voelzke, Henry ;
Felix, Stephan B. ;
Schipf, Sabine ;
Doerr, Marcus ;
Rosskopf, Dieter ;
Nauck, Matthias ;
Schoefl, Christof ;
Wallaschofski, Henri .
DIABETES, 2009, 58 (09) :2027-2031
[22]  
Heinemann L A J, 2005, J Endocrinol Invest, V28, P34
[23]   Fifty-two-Week Treatment With Diet and Exercise Plus Transdermal Testosterone Reverses the Metabolic Syndrome and Improves Glycemic Control in Men With Newly Diagnosed Type 2 Diabetes and Subnormal Plasma Testosterone [J].
Heufelder, Armin E. ;
Saad, Farid ;
Bunck, Mathijs C. ;
Gooren, Louis .
JOURNAL OF ANDROLOGY, 2009, 30 (06) :726-733
[24]   Waist Circumference and All-Cause Mortality in a Large US Cohort [J].
Jacobs, Eric J. ;
Newton, Christina C. ;
Wang, Yiting ;
Patel, Alpa V. ;
McCullough, Marjorie L. ;
Campbell, Peter T. ;
Thun, Michael J. ;
Gapstur, Susan M. .
ARCHIVES OF INTERNAL MEDICINE, 2010, 170 (15) :1293-1301
[25]   Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study [J].
Kalinchenko, Svetlana Y. ;
Tishova, Yuliya A. ;
Mskhalaya, George J. ;
Gooren, Louis J. G. ;
Giltay, Erik J. ;
Saad, Farid .
CLINICAL ENDOCRINOLOGY, 2010, 73 (05) :602-612
[26]   Testosterone: a metabolic hormone in health and disease [J].
Kelly, Daniel M. ;
Jones, T. Hugh .
JOURNAL OF ENDOCRINOLOGY, 2013, 217 (03) :R25-R45
[27]   Waist circumference and cardiometabolic risk: a consensus statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association [J].
Klein, Samuel ;
Allison, David B. ;
Heymsfield, Steven B. ;
Kelley, David E. ;
Leibel, Rudolph L. ;
Nonas, Cathy ;
Kahn, Richard .
AMERICAN JOURNAL OF CLINICAL NUTRITION, 2007, 85 (05) :1197-1202
[28]   Hypertriglyceridemic waist -: A marker of the atherogenic metabolic triad (hyperinsulinemia;: hyperapolipoprotein B;: small, dense LDL) in men? [J].
Lemieux, I ;
Pascot, A ;
Couillard, C ;
Lamarche, B ;
Tchernof, A ;
Alméras, N ;
Bergeron, J ;
Gaudet, D ;
Tremblay, G ;
Prud'homme, D ;
Nadeau, A ;
Després, JP .
CIRCULATION, 2000, 102 (02) :179-184
[29]   Association of Testosterone and Sex Hormone-Binding Globulin With Metabolic Syndrome and Insulin Resistance in Men [J].
Li, Chaoyang ;
Ford, Earl S. ;
Li, Benyi ;
Giles, Wayne H. ;
Liu, Simin .
DIABETES CARE, 2010, 33 (07) :1618-1624
[30]   Prevalence, Pathophysiology, Health Consequences and Treatment Options of Obesity in the Elderly: A Guideline [J].
Mathus-Vliegen, Elisabeth M. H. ;
Basdevant, Arnaud ;
Finer, Nick ;
Hainer, Vojtech ;
Hauner, Hans ;
Micic, Dragan ;
Maislos, Maximo ;
Roman, Gabriela ;
Schutz, Yves ;
Tsigos, Constantine ;
Toplak, Hermann ;
Yumuk, Volkan ;
Zahorska-Markiewicz, Barbara .
OBESITY FACTS, 2012, 5 (03) :460-483